MAA Update on Mestinon Supply – 25 January 2023
More good news about Mestinon supply improving for both 60mg and 180mg! The Mestinon supply shortage has been an evolving issue over the last few months and the MAA has been actively monitoring the situation and speaking with government and industry stakeholders to ensure we can access this important medication. We thank you for contacting us and your state associations with your feedback and we appreciate this has been concerning and sometimes frustrating. Please see the latest update below.
The shortage of Mestinon Timespan 180mg tablets is now expected to resolve on 31 January 2023. The supplier iNova have confirmed they have received 180mg stock. They have despatched backorders and can now fill new orders for their wholesalers. Approximate dates wholesalers should be able to fulfil pharmacy orders are:
NSW, VIC, ACT & QLD: 1 February 2023
SA & NT: 3 February 2023
WA, TAS & NORTH QLD: 6 February 2023
Please note there may still be a few days for your pharmacist to then receive your order and get it to you.
To meet demand throughout January, Medsurge received a second Section 19A approval for another 180mg product (MESTINON-SR pyridostigmine bromide 180 mg slow-release tablets Canada) and they have confirmed sufficient supply of this product with the TGA. However, please be aware that the PBS listing for this particular product had not yet been approved at the time of writing this update.
We encourage you to speak with your pharmacist and ensure they are aware of iNova’s recent stock arrival and the resumption of usual processes for 180mg supply.
The shortage issue has been resolved and supply has resumed. Pharmacists can access 60mg from their usual wholesaler.
The TGA have assured us they will continue to monitor the supply of Mestinon and facilitate patient access where possible.
Susan White, MAA Chairperson
Natalie Windle, MAA Secretary
Glenda Bidner, MAA Board Member